The Quest for a Functional Cure: Moving Beyond Insulin Dependence
For the roughly 2 million adults in the U.S. Living with Type 1 diabetes, the daily grind of insulin pumps and glucose monitoring is a lifelong reality. However, recent developments in islet transplantation and immunosuppressive therapy are signaling a shift toward what some experts call a “functional cure.” A pilot study at the University of Chicago has demonstrated that adults with Type 1 diabetes can achieve complete insulin independence following the transplant of pancreatic insulin-producing cells, known as islets. While islet transplantation has been explored since 2000, the challenge has always been the body’s immune response and the toxicity of the drugs used to prevent rejection. The latest breakthrough involves a combination therapy: the islet transplant paired with a daily anti-rejection pill and an experimental anti-CD40L monoclonal antibody called tegoprubart (AT-1501), developed by Eledon Pharmaceuticals. In this study, 11 participants were able to stop using insulin entirely.
Solving the Toxicity Puzzle: The Role of Tegoprubart
The primary obstacle to successful islet transplantation hasn’t just been rejection, but “transplant-related immune toxicity.” To preserve the new cells alive, patients typically need ongoing immunosuppressive therapy, which can come with severe side effects. Tegoprubart aims to change this equation. In Phase 1B and Phase 2 clinical trials involving kidney transplant patients, this investigational drug provided necessary immunosuppression without the same level of toxicities seen with traditional treatments. In the current Type 1 diabetes study, the drug has provided enough protection to prevent transplant rejection with “no evidence” of the toxicities associated with older treatments. By reducing the biological “cost” of the transplant, this approach makes the procedure more viable for a broader range of patients.
The Hurdle of Durability: Will the Results Last?
While the immediate results are unprecedented, medical experts urge cautious optimism. The central question is not whether patients can stop taking insulin, but for how long. Mandy Ford, scientific director of Atlanta’s Emory Transplant Center, notes that the potential for a cure depends on a “sizeable ‘if’”—whether this insulin independence can be maintained without major side effects over the long term. The history of islet transplantation provides a sobering perspective. A landmark study published in the New England Journal of Medicine found that while 58% of patients initially got off insulin, 76% of those individuals required insulin again within two years. Because the current tegoprubart participants were dosed relatively recently, researchers are still waiting to see if this new drug can break that cycle of relapse.
Scaling the Solution: Overcoming the Islet Shortage
Even if tegoprubart proves to be a permanent solution for insulin independence, a massive logistical hurdle remains: supply. Currently, insulin-producing islets can only be obtained from deceased donors. As Allan Kirk, a transplant surgeon at Duke University, points out, the shortage of available islets is a “critical limiter” that prevents this treatment from being applied on a broad scale. For a small number of people who gain access, it is a functional cure; for the millions of others, the waiting list is the primary barrier. The future of the field likely lies in the marriage of two different technologies:
- Advanced Immunosuppression: Drugs like tegoprubart that protect the transplant without toxic side effects.
- Bioengineering: Companies like Vertex Pharmaceuticals are working to genetically engineer islets, which would remove the reliance on deceased donors.
If scientists can pair a generated, lab-grown source of islets with a non-toxic protector like tegoprubart, the medical community could potentially move from treating Type 1 diabetes to curing it for the entire population.
What This Means for the Future of Diabetes Care
The level of patient interest in these trials is already reaching a fever pitch. Laura Tremblay, a clinical trial education volunteer at Breakthrough T1D, reports an unprecedented spike in patient awareness, with individuals reaching out directly to inquire about the study. As Eledon Pharmaceuticals seeks guidance from the FDA to initiate Phase 3 clinical trials, the focus will shift toward larger, multicenter studies to confirm safety and durability. New studies are being prepared to test the treatment specifically for patients who suffer from both Type 1 diabetes and kidney dysfunction.
Frequently Asked Questions
Is this a guaranteed cure for Type 1 diabetes?
Not yet. While 11 participants stopped using insulin, researchers must still determine if this independence is permanent. Larger, longer-term studies are required to confirm if it is a durable cure. How does tegoprubart differ from traditional anti-rejection drugs?
Unlike older drugs like tacrolimus, which can be toxic to the kidneys and islet cells, tegoprubart is designed to provide immunosuppression without those specific toxicities. Can anyone get an islet transplant?
Currently, no. Access is limited by the availability of islets from deceased donors and the specific eligibility requirements of clinical trials. What is the next step for this treatment?
The developers plan to seek FDA guidance for Phase 3 clinical trials, which are the final step before a drug can be approved for general medical use.
Join the Conversation: Do you reckon bioengineered organs are the ultimate solution to the organ shortage, or should the focus remain on improving donor systems? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on medical breakthroughs.
